ESR1 and breast carcinoma: This has led to a dramatic increase in the number of clinical studies investigating drugs targeting this pathway, and to the approval of the mTOR inhibitor everolimus and the PIK3CA inhibitor alpelisib combined with endocrine therapy in ER+ advanced breast cancer patients previously treated with antiestrogen therapy.